Pasternack A - Search Results

1

Enhanced exercise and regenerative capacity in a mouse model that violates size constraints of oxidative muscle fibres.

Omairi S, Matsakas A, Degens H, Kretz O, Hansson KA, Solbrå AV, Bruusgaard JC, Joch B, Sartori R, Giallourou N, Mitchell R, Collins-Hooper H, Foster K, Pasternack A, Ritvos O, Sandri M, Narkar V, Swann JR, Huber TB, Patel K. Omairi S, et al. Among authors: pasternack a. Elife. 2016 Aug 5;5:e16940. doi: 10.7554/eLife.16940. Elife. 2016. PMID: 27494364 Free PMC article.

2

Inhibition of oocyte growth factors in vivo modulates ovarian folliculogenesis in neonatal and immature mice.

Myllymaa S, Pasternack A, Mottershead DG, Poutanen M, Pulkki MM, Pelliniemi LJ, Ritvos O, Laitinen MP. Myllymaa S, et al. Among authors: pasternack a. Reproduction. 2010 Mar;139(3):587-98. doi: 10.1530/REP-09-0391. Epub 2009 Dec 10. Reproduction. 2010. PMID: 20007639

3

The bioactivity of human bone morphogenetic protein-15 is sensitive to C-terminal modification: characterization of the purified untagged processed mature region.

Pulkki MM, Myllymaa S, Pasternack A, Lun S, Ludlow H, Al-Qahtani A, Korchynskyi O, Groome N, Juengel JL, Kalkkinen N, Laitinen M, Ritvos O, Mottershead DG. Pulkki MM, et al. Among authors: pasternack a. Mol Cell Endocrinol. 2011 Jan 30;332(1-2):106-15. doi: 10.1016/j.mce.2010.10.002. Epub 2010 Oct 16. Mol Cell Endocrinol. 2011. PMID: 20937357

4

Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P, Pasternack A, Kainulainen H, Ritvos O. Hulmi JJ, et al. Among authors: pasternack a. Am J Physiol Endocrinol Metab. 2013 Jan 1;304(1):E41-50. doi: 10.1152/ajpendo.00389.2012. Epub 2012 Oct 31. Am J Physiol Endocrinol Metab. 2013. PMID: 23115080 Free article.

5

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Pasternack A, Kainulainen H, Ritvos O. Hulmi JJ, et al. Among authors: pasternack a. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E171-82. doi: 10.1152/ajpendo.00065.2013. Epub 2013 May 21. Am J Physiol Endocrinol Metab. 2013. PMID: 23695214 Free article.

6

Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.

Kainulainen H, Papaioannou KG, Silvennoinen M, Autio R, Saarela J, Oliveira BM, Nyqvist M, Pasternack A, 't Hoen PA, Kujala UM, Ritvos O, Hulmi JJ. Kainulainen H, et al. Among authors: pasternack a. Mol Cell Endocrinol. 2015 Jan 5;399:131-42. doi: 10.1016/j.mce.2014.10.001. Epub 2014 Oct 7. Mol Cell Endocrinol. 2015. PMID: 25304272

7

Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.

Myllärniemi M, Tikkanen J, Hulmi JJ, Pasternack A, Sutinen E, Rönty M, Leppäranta O, Ma H, Ritvos O, Koli K. Myllärniemi M, et al. Among authors: pasternack a. BMC Pulm Med. 2014 Nov 1;14:170. doi: 10.1186/1471-2466-14-170. BMC Pulm Med. 2014. PMID: 25361680 Free PMC article.

8

Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.

Nissinen TA, Degerman J, Räsänen M, Poikonen AR, Koskinen S, Mervaala E, Pasternack A, Ritvos O, Kivelä R, Hulmi JJ. Nissinen TA, et al. Among authors: pasternack a. Sci Rep. 2016 Sep 26;6:32695. doi: 10.1038/srep32695. Sci Rep. 2016. PMID: 27666826 Free PMC article.

9

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R. Puolakkainen T, et al. Among authors: pasternack a. BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3. BMC Musculoskelet Disord. 2017. PMID: 28103859 Free PMC article.

10

Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.

Hentilä J, Nissinen TA, Korkmaz A, Lensu S, Silvennoinen M, Pasternack A, Ritvos O, Atalay M, Hulmi JJ. Hentilä J, et al. Among authors: pasternack a. Front Physiol. 2019 Jan 18;9:1917. doi: 10.3389/fphys.2018.01917. eCollection 2018. Front Physiol. 2019. PMID: 30713500 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

428 results

Search Page